一个个性化风险模型,用于阿扎西提丁在骨髓质疏松症候群和其他骨髓质神经瘤的结局,通过机器学习模型识别,利用现实世界的数据
Kirsty Sharplin1, William Proudman1, Rakchha Chhetri1,2,3
1Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA 5000, Australia.
Cancers
|August 26, 2023
概括
预测骨髓质疏松症候群 (MDS) 中的阿扎西提丁反应是具有挑战性的. 使用治疗前数据和突变的机器学习模型准确地识别了不太可能受益的患者,从而实现了针对MDS的个性化治疗策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 计算生物学 计算生物学
背景情况:
- 阿扎西提丁是治疗高风险骨髓质疏松症候群 (MDS) 的标准疗法.
- 治疗反应率各不相同 (30-40%),发病时间延迟和骨髓抑制使患者选择复杂化.
- 目前的预后工具缺乏统一性来预测早期治疗失败.
研究的目的:
- 开发和验证MDS患者对阿扎西蒂丁反应的预测模型.
- 为了确定不太可能从前期阿扎西蒂丁治疗中受益的患者.
- 整合基因组数据以提高预后准确度.
主要方法:
- 对273名接受阿扎西提丁治疗的MDS患者的回顾性分析.
- 使用预处理变量开发一个随机森林机器学习模型.
- 整合体质突变数据来完善预测模型.
主要成果:
- 机器学习模型识别出患者的生存率明显较差 (7.99 vs 22.8 个月,p < 0.0001).
- 该模型预测了住院和输血需求,超过了现有的评分系统.
- 纳入体质突变定义了三个不同的风险组,具有差异性生存时间 (5.6,10.5和43.5个月,p < 0.0001).
结论:
- 治疗前的变量和体质突变可以预测MDS中阿扎西提丁的反应.
- 需要个性化的预测工具来优化低甲基化剂治疗.
- 改进的预测可以减少并发症和医疗保健资源利用率.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis
383
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
383


